ChromaDex (CDXC) Announces Publication of Data on NAD+ Precursors NR, NMN
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
ChromaDex Corp. (Nasdaq: CDXC) announced that an additional study recently published in the prestigious journal, Nature Communications, explains why NAD+ precursors (boosters) NR and nicotinamide mononucleotide (NMN) demonstrate similar metabolic benefits in mammals. The study conducted by a team including leading NAD+ researcher, Dr. Charles Brenner, found that effective supplementation with NMN depends on conversion to NR.
NAD+ is a cellular co-enzyme critical for energy production and mitochondrial health. Because NAD+ declines in aging, strategies for NAD+ repletion with B3 vitamins have become popular in order to maintain a youthful metabolism. Recent work also published in Nature Communications and led by Brenner, unequivocally demonstrated that NR is not only the most efficient and effective B3 at upregulating NAD+, but it is also the most effective activator of longevity-promoting sirtuin proteins.
NR is converted to NAD+ in a two-step process initiated by NRK1, a gene discovered by Brenner. Because the product of NRK1 is NMN, Brenner noted that, “Some people believed that NMN would be better at boosting NAD+ levels because NMN comes after NR in the pathway.” Their theory was that NMN could diffuse or be transported into tissues such as the liver and be directly converted to NAD+. “But that theory doesn’t take into account how compounds get into cells,” Brenner explained.
To test the theory, researchers knocked out NRK1 in mice. This enabled them to determine that NMN is converted to NR before entry into liver cells and cannot be converted to NAD+ without the presence of NRK1.
These results explain why NR and NMN have similar benefits in protecting against metabolic disease, neurodegenerative disorders and physiological decline in mammals. Brenner stated, “Anything NMN does, NR is going to be able to do because NMN must become NR to get into cells.”
Asked about his thoughts on the research, ChromaDex’s Founder and CEO, Frank Jaksch, commented, “The body of scientific evidence confirming the importance of NAD+ in promoting healthy aging is overwhelming. With this established, we have seen the conversation shift from ‘How important is NAD+’ to ‘How do we most efficiently and effectively boost NAD+?’ NR continues to prove itself the leader over and over again.”
NR is superior to other forms of vitamin B3 in supporting healthy aging
When it comes to promoting longevity and healthy aging, researchers aim to boost NAD+ and sirtuin activities. Brenner noted that “Neither NMN, niacin, nor nicotinamide are more efficient than NR at boosting NAD+,” and that “Mega-doses of nicotinamide and ribose are not equivalent to NR because high doses of nicotinamide inhibit sirtuin activities.”
A decade’s worth of pre-clinical research as well as recently published human clinical trials have shown that supplementing with NR effectively boosts NAD+ levels. Daily NR supplementation – now widely available as NIAGEN® – safely helps to replenish NAD+ levels. Results from eight additional collaborative human trials currently underway should provide additional insights as to the critical role NAD+ plays in people. For additional information about NIAGEN®, visit www.Chromadex.com.
NAD+ activates cellular metabolism and energy production within the cell’s “power stations,” the mitochondria. Our mitochondria are constantly working to convert the food we eat into the energy necessary to power all bodily systems as well as help us stay healthy enough to ward off illness. The challenge is that both NAD+ levels and mitochondrial functions decline as we age. This reduction in NAD+ is believed by scientists to be linked to a wide variety of age-related conditions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan (AGN) Announces FDA Approval Of RHOFADE Cream to Treat Redness Associated with Rosacea
- Osiris Therapeutics (OSIR) Aannounced Comparative Effectiveness Study on Use of Two Human Placental Membranes in Wound Management
- Cullen/Frost Bankers (CFR) Announces Jack Wood and Royce Caldwell to Leave Board of Directors
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!